v3.24.3
Condensed Consolidated Statements of Operations - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2024 |
Sep. 30, 2023 |
Sep. 30, 2024 |
Sep. 30, 2023 |
|
| Total revenue | $ 56,664 | $ 56,157 | $ 168,853 | $ 175,995 |
| Total cost of revenue | 31,279 | 31,891 | 96,503 | 99,924 |
| Gross margin | 25,385 | 24,266 | 72,350 | 76,071 |
| Operating costs and expenses: | ||||
| Selling, general and administrative | 37,654 | 36,023 | 111,921 | 108,066 |
| Engineering and development | 4,157 | 5,152 | 13,555 | 13,291 |
| Impairment loss | 63,809 | |||
| Total operating costs and expenses | 41,811 | 41,175 | 189,285 | 121,357 |
| Loss from operations | (16,426) | (16,909) | (116,935) | (45,286) |
| Other income (expense): | ||||
| Investment income | 3,059 | 2,848 | 8,468 | 7,962 |
| Interest expense | (889) | (1,357) | (3,472) | (4,197) |
| Gain on extinguishment of debt, net | 17,326 | 5,679 | 18,505 | 5,679 |
| Other income (expense), net | (1,616) | (3,059) | (1,398) | 242 |
| Total other income, net | 17,880 | 4,111 | 22,103 | 9,686 |
| Income (loss) before provision for income taxes | 1,454 | (12,798) | (94,832) | (35,600) |
| Provision for income taxes | (649) | (471) | (1,247) | (1,598) |
| Net income (loss) | 805 | (13,269) | (96,079) | (37,198) |
| Paid-in-kind dividend on Series C Preferred Stock | (2,000) | (2,000) | (6,000) | (6,000) |
| Net loss attributable to common stockholders | $ (1,195) | $ (15,269) | $ (102,079) | $ (43,198) |
| Net loss per share - basic (in dollar per share) | $ (0.02) | $ (0.31) | $ (2.07) | $ (0.89) |
| Net loss per share - diluted (in dollar per share) | $ (0.02) | $ (0.31) | $ (2.07) | $ (0.89) |
| Weighted average shares outstanding - basic (in shares) | 49,417,757 | 48,904,102 | 49,261,717 | 48,660,646 |
| Weighted average shares outstanding - diluted (in shares) | 49,417,757 | 48,904,102 | 49,261,717 | 48,660,646 |
| Life Sciences Services | ||||
| Total revenue | $ 39,278 | $ 36,022 | $ 114,104 | $ 107,062 |
| Total cost of revenue | 21,220 | 20,803 | 63,927 | 59,887 |
| Life Sciences Products | ||||
| Total revenue | 17,386 | 20,135 | 54,749 | 68,933 |
| Total cost of revenue | $ 10,059 | $ 11,088 | $ 32,576 | $ 40,037 |
| X | ||||||||||
- Definition Amount of paid-in-kind dividend on Series C convertible preferred stock. No definition available.
|
| X | ||||||||||
- Definition Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate cost of goods produced and sold and services rendered during the reporting period. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of interest expense classified as nonoperating. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of income (expense) related to nonoperating activities, classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|